Abstract
| Original language | English |
|---|---|
| Journal | Annals of Medicine |
| Volume | 49 |
| Issue number | 1 |
| Pages (from-to) | 63-74 |
| Number of pages | 12 |
| ISSN | 0785-3890 |
| DOIs | |
| Publication status | Published - Feb 2017 |
| MoE publication type | A2 Review article in a scientific journal |
Fields of Science
- 3121 Internal medicine
- aortic valve stenosis
- apelin
- bradykinin
- endothelin
- natriuretic peptides
- renin-angiotensin system
Cite this
}
Targeting vasoactive peptides for managing calcific aortic valve disease. / Peltonen, Tuomas; Ohukainen, Pauli; Ruskoaho, Heikki Juhani; Rysä, Jaana.
In: Annals of Medicine, Vol. 49, No. 1, 02.2017, p. 63-74.Research output: Contribution to journal › Review Article › Scientific › peer-review
TY - JOUR
T1 - Targeting vasoactive peptides for managing calcific aortic valve disease
AU - Peltonen, Tuomas
AU - Ohukainen, Pauli
AU - Ruskoaho, Heikki Juhani
AU - Rysä, Jaana
PY - 2017/2
Y1 - 2017/2
N2 - Calcific aortic valve disease (CAVD) represents a spectrum of disease spanning from milder degrees of calcification of valve leaflets, i.e., aortic sclerosis, to severe calcification i.e., aortic stenosis (AS) with hemodynamic instability. The prevalence of CAVD is increasing rapidly due to the aging of the population, being up to 2.8% among patients over 75 years of age. Even without significant aortic valve stenosis, aortic sclerosis is associated with a 50% increased risk of myocardial infarction and death from cardiovascular causes. To date, there is no pharmacological treatment available to reverse or hinder the progression of CAVD. So far, the cholesterol-lowering therapies (statins) and renin-angiotensin system (RAS) blocking drugs have been the major pharmacological agents investigated for treatment of CAVD. Especially angiotensin receptor blockers (ARB)s and angiotensin convertase enzyme inhibitors (ACEI)s, have been under active investigation in clinical trials, but have proven to be unsuccessful in slowing the progression of CAVD. Several studies have suggested that other vasoactive hormones, including endothelin and apelin systems are also associated with development of AS. In the present review, we discuss the role of vasoactive factors in the pathogenesis of CAVD as novel pharmacological targets for the treatment of aortic valve calcification.
AB - Calcific aortic valve disease (CAVD) represents a spectrum of disease spanning from milder degrees of calcification of valve leaflets, i.e., aortic sclerosis, to severe calcification i.e., aortic stenosis (AS) with hemodynamic instability. The prevalence of CAVD is increasing rapidly due to the aging of the population, being up to 2.8% among patients over 75 years of age. Even without significant aortic valve stenosis, aortic sclerosis is associated with a 50% increased risk of myocardial infarction and death from cardiovascular causes. To date, there is no pharmacological treatment available to reverse or hinder the progression of CAVD. So far, the cholesterol-lowering therapies (statins) and renin-angiotensin system (RAS) blocking drugs have been the major pharmacological agents investigated for treatment of CAVD. Especially angiotensin receptor blockers (ARB)s and angiotensin convertase enzyme inhibitors (ACEI)s, have been under active investigation in clinical trials, but have proven to be unsuccessful in slowing the progression of CAVD. Several studies have suggested that other vasoactive hormones, including endothelin and apelin systems are also associated with development of AS. In the present review, we discuss the role of vasoactive factors in the pathogenesis of CAVD as novel pharmacological targets for the treatment of aortic valve calcification.
KW - 3121 Internal medicine
KW - aortic valve stenosis
KW - apelin
KW - bradykinin
KW - endothelin
KW - natriuretic peptides
KW - renin-angiotensin system
U2 - 10.1080/07853890.2016.1231933
DO - 10.1080/07853890.2016.1231933
M3 - Review Article
VL - 49
SP - 63
EP - 74
JO - Annals of Medicine
JF - Annals of Medicine
SN - 0785-3890
IS - 1
ER -